AMETEK's second quarter landed exactly the way a long-cycle industrial compounder wants a quarter to land three months before signing a $5.0 billion deal: record on every line the company reports. Net sales of $2,044.4 million rose 15% year over year - and almost two-thirds of that growth was organic, a split that matters more than the headline. Adjusted operating income reached $544.4 million (+18%); adjusted diluted earnings per share reached $2.09, a 17% gain. Orders of $2,284.0 million rose 28% on 25% organic growth, and the backlog hit a record $4,110.2 million. Free cash flow conversion hit 111% of net income for the quarter. The reported GAAP numbers tell a quieter story - diluted EPS of $1.77 (+14% on a comparable basis, after stripping a non-cash intangible-amortization add-back of $0.32 per share) - but the adjuster is exactly what investors expect to see at a serial acquirer.
The quarter itself was the easy part. The harder part is what the company is doing with the cash the quarter is generating. On May 6 management announced the all-cash acquisition of Indicor Instrumentation, a portfolio of mission-critical industrial-technology businesses, for roughly $5.0 billion; on June 9 the company replaced the bridge facility with a $3.5 billion revolver (upsized from $2.3 billion) and a $4.0 billion senior unsecured term loan in three tranches; on August 7 the commercial paper program was upsized to $3.5 billion to handle funding on the closing day. Indicor is expected to close in the second half of 2026. In the meantime, full-year 2026 guidance was raised for the second time this year: adjusted EPS to a $8.20–$8.30 range from a prior $7.94–$8.14, with the third quarter alone guided to $2.08–$2.10. The market read the print as confirmation that the model is still compounding - the stock touched a fresh 52-week high in the session after earnings, within 1% of $260.
There are two ways to frame this quarter. The first is a steady industrial doing what steady industrials do. The second is a company spending a record amount of its own currency to bet on the next decade of compounding, and printing a result good enough that nobody objected. The second reading is the right one. Three months from now, the question will not be whether the second quarter was good. It will be whether Indicor closes, whether integration absorbs the operating momentum, and whether the run-rate margin expansion continues once $4.0 billion of term debt comes onto the balance sheet. The quarter was the setup. The deal is the test.